Mobile

A clinical research study evaluating the possibility to stop the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients who have very small amount of leukemia cells remaining after niloti...

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-003186-18

A clinical research study evaluating the possibility to stop the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients who have very small amount of leukemia cells remaining after nilotinib (Tasigna) treatment

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The purpose of this study is to determine the rate of successful treatment-free remission (TFR) within the first 48 weeks following cessation of treatment in patients who achieved and maintained a molecular response (MR) 4.5 on nilotinib after a switch from imatinib. TFR phase is often referred to as discontinuation phase in other studies.

Critère d'inclusion

  • Ph+ chronic myeloid leukemia (CML)

Liens